Full Press Release Details
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
Miramar, FL August 13, 2021 HCW Biologics Inc. (the Company ) (NASDAQ: HCWB), an innovative
biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and
age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021.
HCW Biologics delivered on a milestone as we achieved our goal of closing our initial public offering on July 22 to raise capital to advance the
clinical development of our lead molecules, stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. We started HCW Biologics three years ago with an idea to develop immunotherapeutic treatments for age-related diseases. Since that time, we applied our expertise in advanced protein engineering to internally develop our TOBITM (Tissue
factOr-Based fusIon) discovery platform and successfully developed immunotherapeutic molecules based on TOBITM technology that can be administered by subcutaneous injection as
well as used in adoptive cell therapy approaches. After extensive studies to assess the molecules we created, we selected two lead molecules, HCW9218 and HCW9302 for clinical development.
HCW Biologics clinical development strategy is to prove the safety and efficacy of both lead molecules individually in future clinical trials, and
eventually combine them as an immunotherapeutic for some of the most difficult to treat age-related diseases. Our gateway indication for our lead molecule, HCW9218, is cancer. Several scientific studies have
revealed that increased normal tissue cellular senescence can promote tumor progression, creating a link between aging and cancer. In preclinical studies, HCW9218 has shown it can reduce chemotherapy-induced tumor and normal tissue senescence
and decrease senescence associated secretory phenotype (i.e., proinflammatory) factors that senescent cells secrete, in particular TGF- . We are wrapping up
IND-enabling activities and expect to submit an Investigational New Drug (IND) application for a Phase 1b/2 clinical trial to assess HCW9218 in the treatment of pancreatic cancer by the end of 2021.
Business Highlights:
Second Quarter Financial Results:
About HCW Biologics:
HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation.
The Company is developing novel immunotherapies designed to improve health by disrupting the link between chronic, low-grade inflammation and age-related diseases such
as cancer, cardiovascular disease, diabetes, neurodegenerative disease and autoimmune disease. HCW uses its Tissue factOr-Based fusIon (TOBITM) discovery platform to
generate designer, novel multi-functional fusion molecules with therapeutic properties for the treatment of inflammaging. Two of HCW s lead discoveries via the TOBITM platform include
molecules HCW9218 and HCW9302, both currently undergoing IND-enabling studies.
Forward Looking Statements:
Statements in this press release contain forward-looking statements that are subject to substantial risks and uncertainties. These
statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as
anticipate, expect, believe, will, may, should, estimate, project, outlook, forecast or other similar words and include, without
limitation, statements regarding successful submission of an IND for Phase 1b/2 clinical trial to assess HCW9218 in the treatment of pancreatic cancer by the end of 2021, reduction of chemotherapy-induced tumor and normal tumor and normal tissue
senescence and decrease senescence associated secretory phenotype factors by HCW9218 and the successful combination of HCW9218 and HCW9302 as an immunotherapeutic for some of the most difficult to treat
age-related diseases. Forward-looking statements are based on the Company s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in
the section titled Risk Factors in the final prospectus related to the Company s initial public offering filed with the Securities and Exchange Commission on July 21, 2021. Forward-looking statements contained in this press
release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.